Dr. Wrangle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414Fax+1 843-937-6110
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Emory University School of MedicineResidency, Internal Medicine, 2005 - 2008
Tulane University School of MedicineClass of 2005
Certifications & Licensure
SC State Medical License 2014 - 2025
MD State Medical License 2008 - 2015
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer Start of enrollment: 2006 Aug 01
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Publications & Presentations
PubMed
- 1536 citationsFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerDavid P. Carbone, Martin Reck, Luis Paz-Ares, Benjamin C. Creelan, Leora Horn
The New England Journal of Medicine. 2017-06-21 - 170 citationsEarly Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and SputumAlicia Hulbert, Ignacio Jusué-Torres, Alejandro Stark, Chen Chen, Kristen Rodgers
Clinical Cancer Research. 2017-04-15 - 40 citationsProspective CT Screening for Lung Cancer in a High-Risk Population: HIV-Positive SmokersAlicia Hulbert, Craig M. Hooker, Jeanne C. Keruly, Travis Brown, Karen M. Horton
Journal of Thoracic Oncology. 2014-06-01
Press Mentions
Dr. Wrangle Discusses Phase 2b QUILT 3.055 Trial at IASLC 2024 World Conference on Lung CancerSeptember 23rd, 2024- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung CancerSeptember 9th, 2024
- FDA, SC Experts Say COVID Boosters Will Help Some Patients — but Not Everyone Gets One YetAugust 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
